TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

Benzinga Logo Benzinga By Prnewswire
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against MoonLake Immunotherapeutics for allegedly misleading investors about its drug candidate sonelokimab, which resulted in a 90% stock value drop after a Phase 3 trial disclosed 'disastrous results'.

Insights
NVDA   positive

Top holding in QQQ, part of high-performing tech sector portfolio


MLTX   negative

Company allegedly made false statements about drug candidate, misled investors, and experienced significant stock value decline after poor trial results